Indian-American scientist discovers new biomarker for obsessive compulsive disorder
New Delhi: A team of researchers led by an Indian-American scientist Dr Sameer Sheth has identified a specific neural activity pattern for patients who suffer from obsessive-compulsive disorder (OCD) and have undergone deep brain stimulation (DBS) for its treatment.
The team’s goal was to determine how low-frequency brain oscillations in the theta (4-8 Hertz) to alpha (8-12 Hertz) range, which have been shown in a substantial body of scientific literature to play an important role in cognitive processes, were altered in people with severe, treatment-resistant OCD.
To accomplish this, the team from Baylor College of Medicine and Texas Children’s Hospital in the US used a novel feature of contemporary DBS devices: the ability to record brain activity in addition to providing stimulation.
Unlike most studies, which are done in lab conditions, this one was done in real-life situations.
Before DBS, predictable and periodic neural activity was seen and after its activation, symptomatic reactions were seen, because DBS helps the patients let go of their phobias and embedded responses, allowing them to behave more normally, the researchers noted in the study published in the journal Nature Medicine.
“This neuro-psychological biomarker can serve as a better litmus test to check on the improvements in the lives of people having OCD and could be used for other debilitating conditions as well for they stem from similar neural patterns,” said Dr Sheth at Baylor College of Medicine.
OCD is a prevalent and debilitating mental health illness that affects approximately 2-3 per cent of the global population. In severe circumstances, patients spend a significant amount of time engaging in repetitive compulsions and dwell on intrusive ideas.
OCD has a significant impact on the health and quality of life of patients and careers. Approximately 20-40 per cent of people with severe OCD are resistant to traditional therapies.
Since the early 2000s, DBS therapy has been utilised to control neural activity in specific areas of the brain associated with OCD symptoms.
